175 related articles for article (PubMed ID: 29113666)
21. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Li S; Wang Z; Huang J; Cheng S; Du H; Che G; Peng Y
BMC Cancer; 2016 Nov; 16(1):877. PubMed ID: 27835987
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis.
van den Boorn HG; Stroes CI; Zwinderman AH; Eshuis WJ; Hulshof MCCM; van Etten-Jamaludin FS; Sprangers MAG; van Laarhoven HWM
Crit Rev Oncol Hematol; 2020 Oct; 154():103069. PubMed ID: 32818901
[TBL] [Abstract][Full Text] [Related]
23. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
[TBL] [Abstract][Full Text] [Related]
24. Association of miR-203 Expression with Prognostic Value in Patients with Esophageal Cancer: A Systematic Review and Meta-Analysis.
Cheng Q; Chen L; Ni L
J Invest Surg; 2023 Dec; 36(1):2285780. PubMed ID: 38047456
[TBL] [Abstract][Full Text] [Related]
25. Treatment strategies in recurrent esophageal or junctional cancer.
Butter R; Lagarde SM; van Oijen MGH; Anderegg MCJ; Gisbertz SS; Meijer SL; Hulshof MCCM; Bergman JJGHM; van Berge Henegouwen MI; van Laarhoven HWM
Dis Esophagus; 2017 Sep; 30(9):1-9. PubMed ID: 28859371
[TBL] [Abstract][Full Text] [Related]
26. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract][Full Text] [Related]
27. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
[TBL] [Abstract][Full Text] [Related]
28. [Biomarkers of predicting response to neoadjuvant chemoradiotherapy in esophageal cancer].
Fu JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):805-10. PubMed ID: 24061981
[TBL] [Abstract][Full Text] [Related]
29. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
[TBL] [Abstract][Full Text] [Related]
30. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
31. Radio(chemo)therapy plus resection versus radio(chemo)therapy alone for the treatment of stage III esophageal cancer.
Rades D; Schulte R; Yekebas EF; Homann N; Schild SE; Dunst J
Strahlenther Onkol; 2007 Jan; 183(1):10-6. PubMed ID: 17225940
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma.
Luo H; Cui YY; Zhang JG; Sun YN; Zheng XL; Yang CL; Ye K; Ge H
Clin Transl Oncol; 2018 Jul; 20(7):889-898. PubMed ID: 29143229
[TBL] [Abstract][Full Text] [Related]
33. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
[TBL] [Abstract][Full Text] [Related]
35. Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis.
Janmaat VT; van Olphen SH; Biermann KE; Looijenga LHJ; Bruno MB; Spaander MCW
PLoS One; 2017; 12(10):e0186305. PubMed ID: 29059206
[TBL] [Abstract][Full Text] [Related]
36. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
37. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
Tanaka K; Miyata H; Yamasaki M; Sugimura K; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S607-15. PubMed ID: 23838916
[TBL] [Abstract][Full Text] [Related]
38. Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy.
Nakamura T; Hayashi K; Ota M; Ide H; Takasaki K; Mitsuhashi M
Dis Esophagus; 2004; 17(4):315-21. PubMed ID: 15569370
[TBL] [Abstract][Full Text] [Related]
39. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
[TBL] [Abstract][Full Text] [Related]
40. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?
Voncken FE; Jiang H; Kim J; Guindi M; Brierley J; Knox J; Liu G; Horgan AM; Lister J; Darling G; Metser U; Wong RK
Dis Esophagus; 2014 Aug; 27(6):552-9. PubMed ID: 23121504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
